 |
|
Data presented demonstrate prolonged overall survival for patients with acute myeloid leukemia
December 11, 2008The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR).
AML is a cancer of myeloid blood cells where abnormal cells accumulate in the bone marrow and interfere with normal blood cell production. Patients with AML typically have a poor prognosis and do not respond well to conventional chemotherapy. Roughly 30 percent of patients diagnosed with MDS will progress to AML.
Dr. Pierre Fenaux, of the University of Paris, presented the updated results from an international phase III trial (AZA-001) which was the first study to show an increased overall survival for higher-risk MDS patients. One-third of patients enrolled in the trial met the World Health Organization (WHO) criteria for AML. This analysis showed that 50 percent of the AML patients who were treated with VIDAZA survived at least two years, compared to only 16 percent of patients treated with CCR.
"The data presented at this year's ASH Meeting are encouraging for both physicians and patients and demonstrate the major advancements that have been made in treating hematologic conditions, like MDS and AML, over the past several years," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "We are hopeful about the potential of novel therapies, like VIDAZA, which are helping patients to live longer with a better quality of life."
The data presented today are a follow-up to results from the AZA-001 trial presented at the American Society of Clinical Oncology Meeting in June, which showed that patients with high-risk MDS who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.
MDS Foundation
"The data presented at this year's ASH Meeting are encouraging for both physicians and patients and demonstrate the major advancements that have been made in treating hematologic conditions, like MDS and AML, over the past several years," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "We are hopeful about the potential of novel therapies, like VIDAZA, which are helping patients to live longer with a better quality of life."
The data presented today are a follow-up to results from the AZA-001 trial presented at the American Society of Clinical Oncology Meeting in June, which showed that patients with high-risk MDS who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.
MDS Foundation
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Placebo Miscarriage Nanomaterial Allergic Reaction Heart Surgery Antarctic Cancer Treatment Heart Attack Coffee Gold Nanoparticles Fatty Acids Volcanic Eruption Synthetic Biology Monsoon Radiation Exposure Silicon Cancer Drug Puberty Caesarean Asteroids Aspirin Addiction Enzyme Body Fat Stomach Cancer
See More: Science News Tags
Acute Myeloid Leukemia Current Events and Acute Myeloid Leukemia News RSSNovel epigenetic markers of melanoma may herald new treatments for patients
Melanoma is the most serious form of skin cancer, diagnosed in more than 50,000 new patients in the United States annually. While the rate of incidences continues to rise, survival rate has not improved and the race is on to find the genetic and cellular changes driving melanoma and to devise new means of detection and treatment.
Novel therapy may prove effective in treatment of 30 percent of cancers
A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients.
Researchers find drug that inhibits acute leukemia cell growth
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered how to turn off a certain receptor that promotes the growth of leukemia cells.
A miR boost enables acute leukemia cells to mature
A new study by Ohio State University cancer researchers shows that boosting the level of a molecule called miR-29b in acute myeloid leukemia (AML) cells can reverse gene changes that trap the cells in an immature, fast growing state of development.
CSHL team develops mouse models of leukemia that predict response to chemotherapy
Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment. Just as important, knowing which of a patient's cancer-causing genetic lesions are contributing to drug resistance might help doctors redesign therapy for maximum benefit.
Clinical trial demonstrates safety of pre-transplant expansion of umbilical cord blood stem cells
Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient's blood supply is as safe as a standard cord blood transplant, researchers reported today at the 50th Annual Meeting of the American Society of Hematology.
Research on the effects of stem cell source and patient age on transplantation outcomes
Blood cancers - leukemia, lymphoma, and myeloma - are typically treated with a combination of treatments including chemotherapy, biological therapy, radiation therapy, and stem cell transplantation. Stem cell transplantation is the process by which blood stem cells are collected from a donor, or from the patient prior to chemotherapy, and then infused into the patient after treatment.
Gene mutation improves leukemia drug's effect
Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.
Molecules might identify high-risk acute-leukemia patients
New research suggests that certain small molecules used by cells to control the proteins they make might also help doctors identify adult acute-leukemia patients who are likely to respond poorly to therapy.
Daisies lead scientists down path to new leukemia drug
A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood.
More Acute Myeloid Leukemia Current Events and Acute Myeloid Leukemia News Articles
 |
The Official Patient's Sourcebook on Adult Acute Myeloid Leukemia by James N. Parker (Editor), Philip M. Parker (Editor) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to adult acute myeloid leukemia (also Acute granulocytic leukemia; acute myelocytic leukemia; Acute myeloid leukemia; Acute nonlymphoblastic leukemia; Acute nonlymphocytic leukemia), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some... |
 |
Acute Myelogenous Leukemia (Contemporary Hematology) by Judith E. Karp (Editor) Acute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. Bringing together new concepts and findings in the basic and clinical science of AML, the book emphasizes the molecular basis for new therapies that stand to have the greatest potential impact on the clinical face of these diseases. The text provides insights into selected novel strategies currently and prospectively being developed, including interruption of specific signal transduction pathways, modulation of gene expression, attempts to reinstate... |
 |
Fight Against Acute Myeloid Leukemia T-shirt Large White |
 |
Beating Acute Myeloid Leukemia Together Mug by Design a Product LLC Text on mug: Beating Acute Myeloid Leukemia Together * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
 |
Can We Cure the Common Leukemias? |
 |
Chronic Myeloid Leukemia by Taylor & Francis In this volume, an international team of experts in chronic myeloid leukemia share their expertise. In particular, they contribute their insights on the latest advances in understanding this disease, and the implications those developments have for its management. They explore many topics, including a review of molecular and cellular biology, discussion of conventional chemotherapy and interferon therapy, and recent developments in allografting and autografting. The reader gains not only an incisive view of the biological structure of the disease, but applications of that biology to treatment modalities. Chronic Myeloid Leukemia is ideal for oncologists and other specialists in the field. |
 |
Leukemia: Acute myeloid leukemia, Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia, Myeloid leukemia by John McBrewster (Editor), Frederic P. Miller (Editor), Agnes F. Vandome (Editor) Leukemia (British English: leukaemia) (Greek leukos ?e????, "white"; aima a?µa, "blood") is a cancer of the blood or bone marrow and is characterized by an abnormal proliferation (production by multiplication) of blood cells, usually white blood cells (leukocytes). Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader group of diseases called hematological neoplasms. Leukemia is clinically and pathologically subdivided into several large groups. |
 |
21st Century Ultimate Medical Guide to Acute Myeloid Leukemia (AML or ANLL) - Authoritative, Practical Clinical Information for Physicians and Patients, Treatment Options (Two CD-ROM Set) by PM Medical Health News (Author) This up-to-date and comprehensive set of two CD-ROM discs provides a superb collection of official Federal government documents on Acute Myeloid Leukemia: signs and symptoms, diagnosis, lab tests, treatment and management options, and ongoing clinical research. Every aspect of the disease is thoroughly covered.. Acute myeloid leukemia is a quickly progressing disease in which too many immature white blood cells (not lymphocytes) are found in the blood and bone marrow. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL. For patients, practical information is provided in clearly written patient education documents. For medical professionals, doctor references and texts have detailed technical information and clinical... |
 |
Cure Acute Myeloid Leukemia Sweatshirt Medium White |
 |
Fight Against Acute Myeloid Leukemia Keychain by Design a Product LLC Text on keychain: Fight Against Acute Myeloid Leukemia * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
| © 2009 BrightSurf.com |